Posted on 18/03/2010 in Pharmaceutical Company Product News AstraZeneca has published clinical study data which underlines the efficacy of its oral antiplatelet drug Brilique in treating acute coronary syndromes.
The performance of the pharmaceutical company's treatment was compared against the alternative option clopidogrel among 1,261 patients tested seven days prior to having heart bypass surgery.
It was found that those using Brilique experienced a 51 per cent reduction in mortality rates compared to the clopidogrel group, which means that the study accomplished its primary endpoint.
In addition, it was found that rates of severe bleeding relating to the coronary artery bypass graft surgery were not significantly different between the two patient groups.
Brilique remains the subject of regulatory review in both Europe and the US, where it is marketed under the name Brilinta.
Earlier this month, the company acquired the rights to license and market a range of generic drugs from Torrent Pharmaceuticals, allowing it to expand its activities in the sector.Other news stories from 18/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
